Savara, Inc. · NASDAQ:SVRA

Savara — American Thoracic Society (ATS) 2026 International Conference

9 slides from Savara's conference presentation, May 18, 2026

  1. Slide 1: Molgramostim Improves Exercise Distance and Duration in Patients with aPAP: IMPALA-2 Phase 3 Results

    Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Phase 3 Clinical Trial Bruce C. Trapnell, MD Translational Pulmonary Science Center Cincinnati Children’s Hospital Medical Center Cincinnati, OH USA Prese

  2. Slide 2: Financial Disclosures

    Financial Disclosures  BCT has received grants or contracts from the National Center for Advancing Translational Sciences; has been a consultant for Partner Therapeutics and Savara Inc.; and has an unpaid role as a Scientific Director and Board Chairman at the PAP Foundation.  The IMPALA-2 clinica

  3. Slide 3: Background and Objective

    Background and Objective • Autoimmune PAP (aPAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli, leading to respiratory distress, hypoxemia, and increased infection risk1-3 • Autoimmune PAP is caused by autoantibodies that block granulocyte-macrophage colony- s

  4. Slide 4: Study Design

    Study Design Design • Randomized, double-blind, placebo-controlled Phase 3 clinical trial being conducted at 43 clinical sites across 16 countries • 48-week double-blind intervention period (completed) followed by a 96-week open-label treatment period (ongoing) Endpoints • Primary: Change from basel

  5. Slide 5: Molgramostim Improved Distance Walked (Meters)

    Molgramostim Improved Distance Walked (Meters) Greater mean improvement in distance walked was observed in molgramostim-treated patients compared with placebo at Week 48 LSM Change from Baseline ETD P-Value Week 48 MOL: 167.0 80.6 0.0301 PBO: 86.4 CI, confidence interval; ETD, estimated treatment di

  6. Slide 6: Molgramostim Improved Distance Walked (Meters): Responder Analysis

    Molgramostim Improved Distance Walked (Meters) Responder Analysis* Responder Defined as Having an Increase from Baseline of ≥30 Meters1 or ≥50 Meters2 *Logistic regression model was used and adjusted for baseline distance walked as a continuous covariate, and treatment, region, and percent predicted

  7. Slide 7: Molgramostim Improved Duration of Exercise (Minutes)

    Molgramostim Improved Duration of Exercise (Minutes) Molgramostim patients were able to exercise for longer periods of time compared with patients who received placebo LSM Change from Baseline ETD P-Value Week 48 MOL: 2.0 1.0 0.0262 PBO: 1.0 CI, confidence interval; ETD, estimated treatment differen

  8. Slide 8: Conclusions

    Conclusions  IMPALA-2 is the first aPAP trial to assess exercise capacity using a standardized exercise treadmill test  Consistent with improvement in peak metabolic equivalents, molgramostim improved distance walked and duration of exercise at Week 48 compared with placebo, supporting the potenti

  9. Slide 9: Thank you!

    Authors: Cormac McCarthy,1 Francesco Bonella,2 Yoshikazu Inoue,3,4 Bruce C. Trapnell,5 Tisha Wang,6 Ali Ataya,7 Ross Arena,8 Brian Robinson,8 Rosanna Fleming,8 Yasmine Wasfi,8 Raymond Pratt8 1. School of Medicine, University College Dublin, St. Vincent's University Hospital, Elm Park, Dublin, Thank

Savara — American Thoracic Society (ATS) 2026 International Conference on 6ix